Antihistamine (non-drowsy)

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Antihistamine (non-drowsy)

Cetirizine, loratadine and similar. Seasonal use is worth logging — allergy load itself affects sleep and training quality.

Evidence category: Reference only. This describes the source category, not approval or certainty.

Regulatory statement in source: FDA-approved.

Cetirizine and loratadine are second-generation antihistamines. A clinical reference states cetirizine is FDA-approved for allergic rhinitis and chronic hives, was approved in the United States in 1995 and later sold over the counter. A study of FDA adverse-event reports found strong drowsiness signals for both drugs, so the non-drowsy label does not mean drowsiness never occurs. That study counts spontaneous reports, not trial results. Evidence here is reference-level plus report-database analysis.

Benefits reported in the imported source

• Cetirizine treats allergic rhinitis and chronic hives, and is sold over the counter.

Risks and limits

• Adverse-event reports show strong drowsiness signals for both cetirizine and loratadine
• The non-drowsy label does not mean drowsiness never happens
• That analysis counts spontaneous reports, not trial results

Source bottom line: Approved over-the-counter allergy medicines that still show clear drowsiness signals in adverse reports.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

Historical half-life estimate: 8 hours. FDA label, cetirizine Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Cetirizine - StatPearls - NCBI Bookshelf (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
• High-risks drug adverse events associated with Cetirizine and Loratadine
• DailyMed: cetirizine